Qulipta (atogepant) is AbbVie's once-daily oral CGRP receptor antagonist indicated for the preventive treatment of migraine in adults.
Qulipta is AbbVie's atogepant, an oral small-molecule CGRP receptor antagonist taken once daily for the preventive treatment of migraine in adults, marketed through AbbVie's patient and provider channels.
It is a marketed CGRP-class preventive for the same buyer problem as AgoneX Biopharmaceuticals' histamine receptor modulator AGX-201, differing in delivery route.
| Attribute | Qulipta | AGX-201 | |
|---|---|---|---|
| Provider | |  | |
| Founded | 2013 | 2011 | |
| Sells To | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | |
| Ownership | Public | Private |
Provider
Founded 2013
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 2011
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Vyepti (eptinezumab-jjmr) is Lundbeck's intravenous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Emgality (galcanezumab-gnlm) is Eli Lilly's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Emgality (galcanezumab-gnlm) is Eli Lilly's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Nurtec ODT is a Pfizer oral gepant for acute migraine treatment and episodic migraine prevention.
Ajovy (fremanezumab-vfrm) is Teva's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Nurtec ODT is a Pfizer oral gepant for acute migraine treatment and episodic migraine prevention.
Ajovy (fremanezumab-vfrm) is Teva's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
